Who Qualifies for a GLP-1 Prescription in 2026?
The eligibility landscape for GLP-1 receptor agonist prescriptions has shifted substantially since mid-2025. Three separate pathways now exist depending on whether you're pursuing brand-name medication through insurance, brand-name medication through cash-pay telehealth, or compounded versions from licensed telehealth pharmacies.
The clinical threshold hasn't changed: a BMI of 30 or higher qualifies you for anti-obesity pharmacotherapy under every major guideline. If your BMI falls between 27 and 29.9, you'll need at least one weight-related comorbidity — type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease — documented in your medical record.
What has changed is how aggressively payers are enforcing step therapy, how telehealth platforms verify eligibility, and what the new Medicare GLP-1 Bridge program means for beneficiaries who were previously locked out.
The BMI + Comorbidity Table
| BMI Range | Comorbidity Required? | Eligible Medications | Typical Payer Stance |
|---|---|---|---|
| ≥ 40 | No | Wegovy, Zepbound, compounded sema/tirz | Strongest approval odds |
| 35–39.9 | No (recommended) | Same as above | Usually approved with documentation |
| 30–34.9 | No (but helps) | Same as above | May require step therapy first |
| 27–29.9 | Yes — at least one | Same, but some payers restrict | Prior auth almost always required |
| Below 27 | N/A | Generally not eligible | Off-label only; rarely covered |
Embody
Top Pick — $400 CPA
From $249/mo
Injectable semaglutide only. Compounded — not FDA-approved.
Paid link Check Eligibility →Payer-Specific Rules You Need to Know
Insurance coverage breaks into four categories, each with distinct rules:
Commercial / Employer Plans
Large employers are the fastest-growing segment of GLP-1 coverage. By mid-2026, an estimated 40-50% of large employer plans include some anti-obesity medication benefit — up from roughly 25% in early 2025. Most require prior authorization, and many enforce step therapy (requiring documented failure of behavioral intervention first).
Medicare (GLP-1 Bridge Program)
Starting July 1, 2026, the Medicare GLP-1 Bridge program covers Wegovy (injectable and tablet), Zepbound (KwikPen), and Foundayo for eligible Part D enrollees at a $50 monthly copay after deductible. You must have a BMI ≥ 30 (or ≥ 27 with a comorbidity), be enrolled in Part D, and have a prescriber certify you're using the medication alongside a diet-and-exercise lifestyle program. The Bridge was originally set to end December 31, 2026, but CMS extended it through December 31, 2027. Compounded GLP-1s are not covered.
Medicaid
Roughly a dozen states now cover GLP-1s for obesity through Medicaid as of 2026. Coverage terms, formulary placement, and prior auth requirements vary significantly by state. Your state Medicaid agency's formulary is the definitive source.
Cash-Pay Telehealth
No insurance needed. You pay the telehealth provider directly. Eligibility thresholds are typically less restrictive — most require a BMI ≥ 27 — but legitimate providers still perform a medical evaluation. The Yale study flagged that some vendors approve scripts in under five minutes with no clinician interaction, which raises quality-of-care concerns.
Qualifying Comorbidities: The Full List
When your BMI is between 27 and 29.9, the comorbidity you document can determine whether your prescription gets approved or denied. Here's what counts across major payers:
- Type 2 diabetes or prediabetes (A1C ≥ 5.7)
- Hypertension (≥ 130/80 mmHg or on antihypertensive medication)
- Dyslipidemia (elevated LDL, triglycerides, or on a statin)
- Obstructive sleep apnea (documented by sleep study or CPAP use)
- Cardiovascular disease or history of cardiac events
- Non-alcoholic fatty liver disease / MASH
- Polycystic ovary syndrome (PCOS)
- Osteoarthritis of weight-bearing joints
- Chronic kidney disease stage 2-3
Sesame Care
Brand-Name Marketplace
From $99/visit
FDA-approved brand-name medications only (Wegovy, Zepbound, Foundayo). Not compounded.
Paid link Check Eligibility →What the Yale Secret Shopper Study Means for Choosing a Provider
The JAMA study published July 6, 2026, sent shockwaves through the telehealth GLP-1 industry. A Yale medical student created a patient profile and attempted to obtain prescriptions from 49 online vendors. The results were striking: 45 of 49 (91.8%) issued a prescription, roughly 67% required zero clinician interaction, and some approved and shipped within five minutes.
This doesn't mean all telehealth prescribing is unsafe. What it means is that the quality of the medical evaluation you receive varies enormously from one platform to the next. Some platforms conduct thorough video consultations with licensed physicians who review your full medical history. Others essentially run you through an automated questionnaire and rubber-stamp the script.
When choosing a prescriber, look for platforms that require at minimum: (1) a live or asynchronous clinician review — not just an algorithm, (2) verification of your identity and BMI through photos or a video visit, (3) questions about your medication history, thyroid health, and eating disorder screening, and (4) a mechanism to contact your prescriber after the initial visit.
Wellorithm
Science-Forward
From $199/mo
Compounded — not FDA-approved.
Paid link Check Eligibility →